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A B S T R A C T
Fibrosis is the hallmark of pathologic tissue remodelling in most chronic diseases. Despite advances in our
understanding of the mechanisms of ﬁbrosis, it remains uncured. Fibrogenic processes share conserved core
cellular and molecular pathways across organs. In this study, we aimed to elucidate shared and organ-speciﬁc
features of ﬁbrosis using murine precision-cut tissue slices (PCTS) prepared from small intestine, liver and
kidneys. PCTS displayed substantial diﬀerences in their baseline gene expression proﬁles: 70% of the extra-
cellular matrix (ECM)-related genes were diﬀerentially expressed across the organs. Culture for 48 h induced
signiﬁcant changes in ECM regulation and triggered the onset of ﬁbrogenesis in all PCTS in organ-speciﬁc
manner. TGFβ signalling was activated during 48 h culture in all PCTS. However, the degree of its involvement
varied: both canonical and non-canonical TGFβ pathways were activated in liver and kidney slices, while only
canonical, Smad-dependent, cascade was involved in intestinal slices. The treatment with galunisertib blocked
the TGFβRI/SMAD2 signalling in all PCTS, but attenuated culture-induced dysregulation of ECM homeostasis
and mitigated the onset of ﬁbrogenesis with organ-speciﬁcity. In conclusion, regardless the many common
features in pathophysiology of organ ﬁbrosis, PCTS displayed diversity in culture-induced responses and in
response to the treatment with TGFβRI kinase inhibitor galunisertib, even though it targets a core ﬁbrosis
pathway. A clear understanding of the common and organ-speciﬁc features of ﬁbrosis is the basis for developing
novel antiﬁbrotic therapies.
1. Introduction
Excessive scar formation, known as ﬁbrosis, is a common patholo-
gical factor in numerous chronic diseases aﬀecting various organs such
as the liver, kidneys, intestine, lungs and skin, among others.
Pathologies like Crohn's disease, primary biliary cholangitis and chronic
kidney disease cause progressive organ malfunction, resulting in high
morbidity and mortality [1–3]. Despite the fact that diverse factors can
cause aberrant wound healing, the pathogenesis of ﬁbrosis shares a
number of common features across organs [4,5]. Under chronic injury,
ﬁbroblasts diﬀerentiate into myoﬁbroblasts – contractile, alpha smooth
muscle actin (α-SMA) positive cells – that secrete excessive amounts of
extracellular matrix (ECM) proteins and glycoproteins, such as
collagen, ﬁbronectin, elastin, biglycan and decorin [6]. ECM remodel-
ling is regulated by matrix metalloproteinases (MMPs) that degrade
ECM, and their inhibitors – tissue inhibitors of metalloproteinases
(TIMPs). Fibrosis occurs when the balance between MMPs and TIMPs
shifts towards the latter, meaning that the synthesis of new ECM by
myoﬁbroblasts exceeds the rate at which it is degraded [7]. Other
shared characteristics of ﬁbrosis include the release of pro-ﬁbrogenic
cytokines and growth factors, impaired angiogenesis [8] and sustained
inﬂammation [9,10].
Furthermore, ﬁbrosis-associated signalling pathways are highly
conserved between diﬀerent organs. For instance, transforming growth
factor beta (TGFβ) is widely recognized as the key driving force behind
ﬁbrogenesis in essentially all organs [11–15]. Excessive release and
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sustained activity of TGFβ stimulates cellular diﬀerentiation to myoﬁ-
broblasts and pathological ECM turnover [4]. The TGFβ signalling
cascade involves the binding of a ligand to the extracellular domain of
the type II receptor (TGFβRII) that recruits and phosphorylates the type
I receptor (TGFβRI or activin receptor-like kinase 5, ALK5). The acti-
vated receptor complex triggers the recruitment of SMAD proteins
(SMAD2 and SMAD3) that associate with SMAD4 to propagate the
signal [16]. Although TGFβ mainly signals via SMADs, it can also ac-
tivate other, non-canonical pathways such as phosphatidylinositol-3-
kinase (PI3K)/AKT, Rho-like guanosine triphosphatases (GTPases) and
mitogen activated protein kinases (MAPKs), including extracellular
signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK)
[17,18].
Among the available tools to study organ ﬁbrosis, the precision-cut
tissue slices (PCTS) model oﬀers several valuable advantages. Opposed
to conventional in vitro systems, PCTS preserve complex organotypic
architecture and retain cell-cell and cell-matrix contacts [19]. Fur-
thermore, PCTS substantially contribute to the 3Rs by reducing the
number of animals needed for research, since slices can be prepared
from various tissues, enabling simultaneous use of several organs from
one animal. Our group previously demonstrated that PCTS can be used
to study the mechanisms of intestinal ﬁbrosis [20], liver ﬁbrosis
[21,22], renal ﬁbrosis [23,24] and to test the eﬃcacy of putative an-
tiﬁbrotic drugs.
The aim of this study was to uncover the shared and organ-speciﬁc
features of ﬁbrogenesis in the intestine, liver and kidney using murine
PCTS. We explored ECM regulation and involvement of the TGFβ
pathway both on a transcriptional and translational level, and in-
vestigated organ-speciﬁc responses to the treatment with antiﬁbrotic
compound galunisertib. Galunisertib (LY2157299 monohydrate) is a
small molecule inhibitor of TGFβRI/ALK5 kinase that speciﬁcally
downregulates the phosphorylation of SMAD2, and it is currently under
clinical development for the treatment of a variety of cancers [25–27].
This study improves our general understanding of organ ﬁbrosis for the
purposes of basic research and the development of new therapies.
2. Methods
2.1. Animals
Adult C57BL/6J mice (Centrale Dienst Proefdieren, University
Medical Center Groningen, Groningen, The Netherlands) were housed
under controlled conditions with a 12 h:12 h light-dark cycle and free
access to water and food. The experiments were approved by the
Animal Ethical Committee of the University of Groningen (DEC
6416AA-001).
Organs were harvested via a terminal procedure performed under
isoﬂurane/O2 anesthesia (Nicholas Piramal, London, UK). Freshly ex-
cised livers and kidneys were kept in ice-cold University of Wisconsin
(UW) organ preservation solution until slicing. Mouse jejunum was
preserved in ice-cold Krebs-Henseleit buﬀer (KHB) supplemented with
25mM D-glucose (Merck, Darmstadt, Germany), 25mM NaHCO3
(Merck) 10mM HEPES (MP Biomedicals, France), saturated with car-
bogen (95% O2/5% CO2), pH 7.4.
2.2. Preparation of precision-cut tissue slices
Liver, kidney and intestinal PCTS were prepared using a Krumdieck
tissue slicer (Alabama Research & Development Corp., Munford, AL,
USA) according to the protocol described by de Graaf et al. [28] and
Stribos et al. [24], with minor modiﬁcations.
2.2.1. Precision-cut liver slices (PCLS)
Liver tissue cores were made using a 6mm biopsy punch. Slices with
a wet weight of 4–5mg and estimated thickness of 250–300 μm were
prepared in ice-cold KHB and transferred to UW directly after slicing, to
prevent rapid loss of viability. Slices were incubated individually in
1.3 mL of Williams' medium E with GlutaMAX (Life Technologies,
Bleiswijk, the Netherlands) supplemented with 25mM D-glucose
(Merck) and 50 μg/mL gentamicin (Life Technologies) at 37 °C in an
80% O2/5% CO2 atmosphere while gently shaken at 90 rpm.
2.2.2. Precision-cut kidney slices (PCKS)
Whole mouse kidneys were placed in the core holder inside the
tissue slicer to obtain slices with a wet weight of 4–5mg and thickness
of 250–300 μm. Kidney slices were immediately transferred to ice-cold
UW after slicing. Subsequently, PCKS were incubated individually in
1.3 mL of Williams' medium E with GlutaMAX containing 10 μg/mL
ciproﬂoxacin (Sigma-Aldrich, Saint Louis, USA) and 25mM D-glucose
(Sigma-Aldrich) at 37 °C in a 80% O2/5% CO2 atmosphere while gently
shaken at 90 rpm.
2.2.3. Precision-cut intestinal slices (PCIS)
The jejunum was cleaned by ﬂushing KHB through the lumen, the
tissue was subsequently divided into 2 cm segments. These segments
were ﬁlled with 3% (w/v) agarose (Sigma-Aldrich) in 0.9% NaCl at
37 °C and embedded in an agarose core-embedding unit. Intestinal
slices with wet weight of 1–2mg were prepared and stored in ice-cold
KHB, then cultured individually in 0.5mL of Williams' medium E with
GlutaMAX supplemented with 25mM D-glucose, 50 μg/mL gentamicin
and 2.5 μg/mL fungizone (amphotericin B; Life Technologies) at 37 °C
in an 80% O2/5% CO2 atmosphere while gently shaken at 90 rpm.
2.3. Experimental treatment of PCTS with galunisertib (LY2157299)
Galunisertib (LY2157299) was purchased from Selleckhem
(Munich, Germany). Stock solution of 2.5mM was prepared in DMSO
and diluted in the culture medium with a ﬁnal concentration of the
solvent of ≤0.5%. Mouse liver, kidney and intestinal slices were in-
cubated with 10 μM of galunisertib or solvent for 48 h. The tested
concentration of galunisertib was in the range of observed plasma ex-
posure [29,30]. Medium was refreshed every 24 h.
2.4. Viability of PCTS
After incubation, slices were transferred to a sonication solution
(containing 70% ethanol and 2mM EDTA) and snap-frozen [28]. Via-
bility of the slices was assessed by measuring the adenosine tripho-
sphate (ATP) content using the ATP bioluminescence kit (Roche diag-
nostics, Manheim, Germany). The ATP values (pmol) were normalized
to the total protein content (μg) of each slice, estimated by the Lowry
assay (Bio-Rad DC Protein Assay, Hercules, USA). Values are displayed
as relative values compared to the average of a related control.
2.5. Total RNA isolation cDNA synthesis
Total RNA was isolated from pooled snap-frozen slices (three slices
for liver and kidney, six slices for jejunum), using the Qiagen RNAeasy
mini kit (Qiagen, Venlo, The Netherlands). The absorbance ratio 260/
280 was used to assess RNA purity and was considered satisfactory
when values ranged between 1.9 and 2.1. Reverse transcription was
performed with 1 μg total RNA using the Reverse Transcription System
(Promega, Leiden, The Netherlands) at 25 °C for 10min, 42 °C for
15min and 95 °C for 5min.
2.6. Mouse TaqMan low-density array
We used a custom-designed Taqman low-density array (TLDA,
Applied Biosystems, Bleiswijk, The Netherlands) to measure the ex-
pression of 44 genes related to extracellular matrix homeostasis
(Supplementary Table S1). A total of 100 μL reaction mixture con-
taining 6 ng/μL cDNA and 50 μL Taqman Universal PCR Master Mix
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(Applied Biosystems) was transferred into the loading port of a TLDA
card. PCR ampliﬁcation was performed on the Applied Biosystems
ViiA™7 Real-Time PCR System. The most appropriate housekeeping
gene was identiﬁed by NormFinder [31]. Based on these results, Gapdh
was used as an endogenous control. Expression values were calculated
using the 2−ΔCt method [32]. All Ct values above 37 were considered
noise and excluded from further analysis. Normalization of the Ct va-
lues in each sample was carried out as ΔCt=Ct(target)–Ct(Gapdh). The
fold change was calculated comparing the gene expression of each
group with the average of the control expression level: fold change
(FC)= 2−ΔCt(experimental)/mean(2−ΔCt(control)). Gene expression levels
were determined relative to 0 h PCIS for baseline expression proﬁling or
to 0 h of respective PCTS for culture and treatment eﬀects. Variance
stabilization was managed with log2 transformation. The heatmap of
log2(FC) values was generated using the online tool Morpheus (https://
software.broadinstitute.org/morpheus/). Hierarchical cluster analysis
was performed by average-linkage clustering method using Pearson
correlation.
2.7. Quantitative real-time PCR
mRNA expression of key ﬁbrosis markers and genes involved in
TGFβ signalling was determined with qRT-PCR. The RT-PCR reaction














































































































Fig. 1. Preparation, culture and viability of murine precision-cut tissue slices. (a) Graphical summary of the study workﬂow: precision-cut tissue slices were obtained
from murine small intestine (jejunum), liver and kidney by preparing tissue cores that were placed in the Krumdiek tissue slicer. After slicing, PCIS, PCLS and PCKS
were cultured in plastic well-plates (1 slice per well) in the presence or absence of galunisertib for 48 h, then collected (by pooling 3–6 slices of the same tissue type
and animal from at least three individual mice) and subjected to the analysis. (b) Viability of murine PCIS, PCLS and PCKS at 48 h and after the treatment with 10 μM
galunisertib was measured by ATP (pmol) normalized to the total protein content (μg). Data are shown as absolute values to reﬂect the eﬀect of culture or as relative
values to non-treated control slices to reﬂect the eﬀect of galunisertib. Data are expressed as mean (± SEM), n= 3, *p < 0.05.
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Luckenwalde, Germany) on a 7900HT Real Time PCR system (Applied
Biosystems) with a cycle at 95 °C for 10min and 45 cycles of 95 °C for
15 s and 60 °C for 25 s followed by a dissociation stage. The mRNA
expression values were calculated using the 2−ΔCt method, with Gapdh
as a reference gene. The primers (50 μM; Sigma-Aldrich) used in this
study are listed in Supplementary Table S2.
2.8. Western blotting
Three (for liver and kidney) or six (for jejunum) slices were pooled
and lysed in ice-cold RIPA buﬀer (Thermo Scientiﬁc, Waltham,
Massachusetts, USA) supplemented with PhosphoStop (Roche
Diagnostics, Mannheim, Germany) and protease inhibitor cocktail
(Sigma-Aldrich). A total of 90–100 μg of protein was separated by SDS/
PAGE on 10% sodium dodecylsulfate polyacrylamide gel, containing
2,2,2-trichloroethanol (TCE; Sigma-Aldrich) for visible detection of
total protein load [33], and subsequently transferred to an activated
polyvinyl diﬂuoride membrane (Immuno-Blot PVDF, Bio-Rad). Mem-
branes were blocked in TBST with 5% Blotting-Grade Blocker (Bio-Rad)
and incubated with primary antibody (Supplementary Table S3) over-
night at 4 °C. Immunodetection was performed by incubating the
membranes with the appropriate HRP-conjugated secondary antibody.
Protein bands were visualized using Clarity Western ECL Substrate (Bio-
Rad) and ChemiDoc Touch Imaging System (Bio-Rad). Protein expres-
sion was corrected for total protein load and expressed as a relative
value to the control group.
2.9. Statistics
The aforementioned analyses were performed using three to six
pooled slices from the same animal (technical replicates) and repeated
with at least three mice (biological replicates). The results are expressed
as mean ± standard error of mean (SEM). We used GraphPad Prism
6.0 (GraphPad Software Inc.) to carry out statistical data analysis.
Treatment groups were compared by unpaired Student's t-test or one-
way ANOVA followed by Dunnett's multiple comparisons test as ap-
propriate. Protein levels determined by Western blot were compared
using non-parametric Mann-Whitney test. A p-value of< 0.05 was
considered statistically signiﬁcant.
3. Results
We used murine small intestine (jejunum), liver and kidney to
prepare precision-cut tissue slices (PCIS, PCLS and PCKS, respectively)
as illustrated in Fig. 1a. Slices were cultured for 48 h under standard
conditions or treated with TGFβR1 kinase inhibitor galunisertib. Fig. 1b
shows that all slices remained viable at 48 h, in accordance with our
previous reports [24,34]. PCIS displayed a slight decrease in ATP
content, while the ATP levels of PCLS and PCKS signiﬁcantly increased
at 48 h, indicating that ATP production was restored after the cold
ischemia period as a result of slicing. In line with previous reports [22],
galunisertib at 10 μM did not elicit toxicity in PCIS, PCLS or PCKS, as it
had no impact on ATP content.
3.1. Diﬀerential regulation of genes involved in ECM homeostasis in PCTS
To characterize the regulation of ECM homeostasis, we carried out
gene expression proﬁling of tissue slices at 0 h, after 48 h of culture or
after the treatment with a TGFβR1 kinase inhibitor galunisertib. We
performed TaqMan low density array (TLDA) with a panel of 44 genes
related to various ECM components (including six types of collagen),
enzymes involved in collagen processing and ECM remodelling and
ECM protein receptors.
Fig. 2a illustrates the baseline ECM (regulation) expression proﬁles
of PCIS, PCLS and PCKS, as visualized by a heatmap with hierarchical
clustering. Unsupervised cluster analysis of relative expression levels
(log2(FC) values) provided a perfect separation of 0 h PCIS, PCLS and
PCKS, suggesting substantial diﬀerences in the baseline ECM regulation
proﬁles between intestine, liver and kidney. A comparative statistical
analysis revealed that only 13 out of 44 transcripts (30%) had similar
expression levels in all PCTS (Supplementary Table S4). Furthermore,
we identiﬁed seven genes (Plod2, Leprel1, Loxl2,Mmp13, Bmp1, Fn1 and
Ddr2) that were diﬀerentially expressed across all PCTS (Fig. 2b).
Fig. 2c–e illustrates the sets of transcripts that represent distinct sig-
natures in PCTS baseline expression proﬁles. For instance, PCIS at 0 h
highly expressed genes encoding collagens (Col1a1, Col3a1, Col6a1)
and metalloproteinases (Mmp2 and Mmp9). PCLS, in turn, exhibited
characteristically low expression of ﬁve transcripts (Col1a2, Col4a1,
Loxl1, Serpinh1 and Ddr1), while PCKS expressed high levels of other six
mRNAs (Leprel2, Pcolce, Slc39a13, Fmod, Bgn and Mrc2) and low levels
of P4hb and Dcn.
We next examined the impact of 48 h culture and the treatment with
TGFβRI kinase inhibitor (Fig. 3). Both culture and galunisertib in-
troduced considerable changes in the gene expression proﬁles of PCIS,
PCLS and PCKS, as the cluster analysis clearly separated the samples by
time point (0 h vs. 48 h) and treatment (48 h control slices vs. 48 h slices
treated with 10 μM galunisertib) (Fig. 3a–c). The eﬀect of culture in
PCTS is summarized in Fig. 3d and f, and Fig. 3e, g and h detail the
eﬀect of galunisertib. We performed a pairwise comparison of expres-
sion levels in slices at 0 h versus 48 h and identiﬁed 21 (48%), 26 (59%)
and 38 (86%) diﬀerentially expressed genes that achieved statistical
signiﬁcance in PCIS, PCLS and PCKS, respectively (Fig. 3d). The ma-
jority of these transcripts were upregulated in PCLS (92%) and PCKS
(89%), whereas in PCIS 10 out of 21 diﬀerentially expressed genes
(48%) were downregulated during 48 h culture (Fig. 3d), including
Col1a1, Col1a2, Col3a1, Pcolce, Pcolce2, Eln and Bgn. The Venn diagram
(Fig. 3f) illustrates the numbers of overlapping and unique genes in-
ﬂuenced by 48 h culture between PCIS, PCLS and PCKS, followed by the
gene lists. Only nine (20%) transcripts were common in all tissue slices:
besides altered expression of Col1a1, Col1a2 and Col3a1, the organs
showed similar culture-induced increase in P4ha2, Lepre1, Loxl2,
Fkbp10, Mmp13 and Timp1. Furthermore, the number of genes that
were shared across pairs of organs dominated over those that were
unique within each organ. In particular, PCLS and PCKS exhibited more
similar changes in ECM homeostasis at 48 h than their pairwise com-
parisons with PCIS, as 13 transcripts were commonly aﬀected in PCLS
and PCKS, eight transcripts were common between PCIS and PCKS and
only three between PCIS and PCLS. As the largest number of diﬀeren-
tially expressed genes was observed in cultured PCKS, eight of these
genes were unique to PCKS and included Col6a1, Bmp1, P4ha1 (re-
quired for proper collagen folding), Loxl3 (involved in crosslinking of
collagen and elastin), Adamts2 and Adamts3 that are crucial for collagen
ﬁbrils formation, and the ECM protein receptors Ddr2 and Mrc2. The
top two diﬀerentially regulated genes at 48 h in PCIS and PCLS were
Mmp13 (fold change 88.29 ± 23.78 in PCIS, 85.96 ± 7.77 in PCLS)
and Timp1 (fold change 73.21 ± 8.76 in PCIS, 57.89 ± 16.54 in
PCLS), while PCKS showed the most dramatic increase in Mmp9 (fold
change 114.34 ± 49.87) and Timp1 (fold change 684.29 ± 86.05)
(Supplementary Table S5). Overall, the culture-induced changes in ECM
homeostasis indicate the onset of ﬁbrogenesis in PCTS.
When PCTS were treated with 10 μM galunisertib for 48 h, the de-
gree of the response varied between the organs (Fig. 3e). PCKS dis-
played an altered expression of 29 genes (66%) with statistical sig-
niﬁcance. The number of genes aﬀected by galunisertib lowered to nine
(20%) in PCLS, and only ﬁve genes (11%) were signiﬁcantly aﬀected in
PCIS. Notably, the majority of these transcripts were downregulated;
however, some genes were upregulated by galunisertib treatment:
Plod3 (fold change 1.37 ± 0.09 in PCIS), Loxl4 (fold change
1.29 ± 0.12 in PCLS and 1.41 ± 0.14 in PCKS) and Dcn (fold change
3.34 ± 0.12 in PCKS; Supplementary Table S5). Furthermore, statis-
tical analysis revealed that galunisertib signiﬁcantly downregulated a
total of three transcripts across all tissue slices, namely Lox, Col1a1 and
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Col3a1 (Fig. 3g), and the level of downregulation was increasing in the
order PCIS < PCLS < PCKS. For instance, galunisertib inhibited
Col1a1 expression by 48% in PCIS, 87% in PCLS and by 97% in PCKS
(Supplementary Table S5). Of the 44 tested genes, 13 genes remained
unaﬀected in PCTS after treatment (Fig. 3h) and included genes en-
coding prolyl hydroxylases P4ha1, P4ha2 and P4hb, procollagen N-
proteinases Adamts3 and Adamts14, Col4a1 and ECM protein receptors
Ddr1 and Ddr2, among others.
3.2. Regulation of selected markers of ﬁbrogenesis in murine PCTS
To conﬁrm the results of the TLDA, we performed single-gene SYBR
green RT-qPCR for selected transcripts. Fig. 4a shows the mRNA level of
genes encoding for collagen type I (Col1a1), heat shock protein 47
(Serpinh1) and ﬁbronectin (Fn1) in tissue slices at 0 h, after 48 h culture
and after treatment with 10 μM galunisertib. We also included a fourth
marker of ﬁbrogenesis — Acta2, encoding α-SMA that is expressed by
myoﬁbroblasts. The baseline expression of Col1a1, Acta2 and Fn1 was
distinctly higher in PCIS as compared to liver and kidney slices, while
Serpinh1 mRNA level was the lowest in PCLS. All tissue slices developed
a spontaneous ﬁbrogenic response during 48 h culture. We observed a
signiﬁcant upregulation of Serpinh1 and Fn1 in all organs, upregulation
of Col1a1 and no change in Acta2 expression in PCLS and PCKS. Of
note, the magnitude of culture-induced upregulation varied in an
organ-speciﬁc manner: the expression level of ﬁbrogenesis markers
after 48 h culture were consistently and signiﬁcantly higher in PCKS
than in other tissue slices. In contrast to liver and kidney, PCIS dis-
played a signiﬁcant decrease in mRNA levels of Col1a1 and Acta2 at
48 h. Overall, our qPCR results for Col1a1 and Serpinh1 correlated with
TLDA, but not for Fn1: in contrast to TLDA results, PCIS (and not PCLS)
expressed high baseline levels of Fn1, and there was a signiﬁcant up-
regulation at 48 h in PCLS.
To further explore the expression proﬁles of tissue slices from je-
junum, liver and kidney, we measured the expression of ﬁbrosis mar-
kers by Western blot (Fig. 4b). We observed an increased protein ex-
pression of α-SMA and HSP47 after 48 h in all tissue slices, although the
increase of HSP47 in PCLS did not reach statistical signiﬁcance (fold





Fig. 2. Transcriptional analysis of murine precision-
cut tissue slices prior culturing (0 h) by TaqMan low-
density array (TLDA). (a) Heatmap of the expression
patterns of 44 genes associated with extracellular
matrix homeostasis in 0 h PCIS, 0 h PCLS and 0 h
PCKS. The expression levels were calculated as re-
lative to the average expression in 0 h PCIS. Based
on statistical analyses performed on ΔCt values
(Supplementary Table S4), the transcripts were di-
vided in sets and depicted as portions of the (a)
heatmap in the following manner: (b) heatmap il-
lustrating seven genes that were diﬀerentially ex-
pressed in PCIS, PCLS and PCKS at 0 h; (c) heatmap
illustrating genes that are distinct in 0 h PCIS; (d)
heatmap illustrating genes that are distinct in 0 h
PCLS; (e) heatmap illustrating genes that are distinct
in 0 h PCKS. Red and blue indicate relatively high
and low expression, respectively (grey color in-
dicates undetermined values). Row min and max
expression levels were determined for each row se-
parately, therefore min and max values are unique
for each analyzed gene. Unsupervised clustering
analysis was performed by average-linkage clus-
tering method using Pearson correlation; n=3. Full
gene names are listed in Supplementary Table S1,
and absolute expression values for each gene in
PCIS, PCLS and PCKS at 0 h are indicated in
Supplementary Table S4.
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was reduced at 48 h, the protein expression of α-SMA showed a sig-
niﬁcant increase. These results indicate that the ﬁbrogenesis was not
only active on a transcriptional, but also on a translational level.
Galunisertib (10 μM) mitigated the culture-induced onset of ﬁ-
brogenesis in PCKS, as reﬂected by the dramatically reduced mRNA
levels of all tested markers (Fig. 4a). Treatment aﬀected the expression
of three markers in PCLS, namely Col1a1, Acta2 and Fn1, and it only
inhibited Col1a1 expression in PCIS. These qPCR results were in line
with the TLDA. On a protein level, galunisertib showed less pronounced
eﬀects: it only signiﬁcantly decreased α-SMA expression in PCLS and
HSP47 expression in PCKS (Fig. 4b).
To strengthen the evidence that ﬁbrogenic response in tissue slices
is inﬂuenced by the organ type, we evaluated mRNA expression of
Col1a1, Acta2, Serpinh1 and Fn1 in slices prepared from ﬁbrotic livers
(Supplementary Fig. S1). For this purpose, two mouse models of liver
ﬁbrosis were used to generate ﬁbrotic PCLS, namely Mdr2 (Abcb4)−/
− FVB mice that develop spontaneous biliary ﬁbrosis [35] and Balb/c
mice with induced parenchymal liver ﬁbrosis by the administration of
CCl4 [36]. We showed that diseased PCLS displayed a clear ﬁbrotic
genotype prior to culturing: PCLS prepared from ﬁbrotic livers had
signiﬁcantly higher baseline expression of all four markers (except for
Acta2 in PCLS-CCl4) compared to PCLS prepared from livers of control
mice (Supplementary Fig. S1a and c). Furthermore, ﬁbrotic PCLS from
Mdr2−/− and CCl4-treated mice showed similarities in responses to
culture and exposure to galunisertib not only between these two models
of liver ﬁbrosis but also compared to the responses in PCLS obtained
from healthy mice. For instance, similar to healthy PCLS, 48 h culture
induced upregulation of Col1a1, Serpinh1 and Fn1, and galunisertib
inhibited expression of Col1a1 and Acta2, in all ﬁbrotic slices (Sup-
plementary Fig. S1b and d). Some diﬀerences were observed as well: in
contrast to healthy PCLS, ﬁbrotic slices obtained from CCl4-treated mice
showed increased levels of Acta2 during culture, while PCLS from
Mdr2−/− mice showed no response in Fn1 mRNA expression to the
treatment with galunisertib. These deviations might stem from the
diﬀerences in the mouse strains, etiology of liver ﬁbrosis and from the
pre-existing diseased state of ﬁbrotic PCLS. Nevertheless, the partial
overlap in the expression of these four markers between healthy and
ﬁbrotic PCLS indicates that organ type largely dictates the responses of
tissue slices to pro-ﬁbrotic stimuli as well as to the antiﬁbrotic treat-
ment.
Since inﬂammation often accompanies ﬁbrogenesis, we measured
the gene expression of several inﬂammation markers, such as Il-1b, Il-6,
Cxcl1 and Tnf (Supplementary Fig. S2). Tissue slices exhibited diﬀer-
ential basal expression of these proﬁbrotic cytokines. For instance, PCIS
at 0 h highly expressed Il-6 and Tnf, while PCLS had signiﬁcantly higher
levels of Cxcl1. Culturing for 48 h induced a strong inﬂammatory re-
sponse in all organs, while the treatment with galunisertib had no or
little eﬀect on the expression of the tested inﬂammation markers.
3.3. Involvement of canonical and non-canonical TGFβ pathway in
ﬁbrogenesis in PCTS
As mentioned above, TGFβ signalling is an essential element of
organ ﬁbrosis. Therefore, we investigated the involvement of the TGFβ
pathway in the culture-induced onset of ﬁbrogenesis in PCTS by mea-
suring mRNA expression of Tgfb1, Tgfbr1 and Serpine1 (Fig. 5a). The
latter encodes for plasminogen activator inhibitor 1 (PAI-1), which is
tightly regulated by TGFβ and in ﬁbrotic tissues promotes excessive
collagen deposition [37]. Regarding baseline expression of TGFβ
pathway markers, PCIS showed high levels of Tgfb1, PCKS had dis-
tinctly high levels of Serpine1, and there was no diﬀerence in expression
of Tgfbr1 between the organs. As expected, all three markers were
signiﬁcantly upregulated during 48 h culture in PCLS and PCKS, con-
ﬁrming the active involvement of the TGFβ pathway in the onset of
ﬁbrosis. PCIS also showed an increase in mRNA levels of Tgfb1 and
Serpine1 (at a lower degree as compared to PCKS), but the Tgfbr1 ex-
pression remained unchanged. Treatment with the TGFβR1 kinase in-
hibitor galunisertib only eﬀectively blocked the TGFβ pathway in PCKS,
while it failed to aﬀect the gene expression of all three markers in PCLS
and PCIS.
Since the activated TGFβRII-TGFβI/ALK5 complex phosphorylates
SMAD2 (pSMAD2) [16], the changes in pSMAD2 can be used to de-
termine the activity of the TGFβ pathway as well as the eﬃcacy of TGFβ
inhibitors. Along with pSMAD2, we measured the protein expression of
pSMAD1 – the downstream molecule of TGFβRI/ALK1 signalling [38].
As predicted, pSMAD2 was signiﬁcantly increased during culture to a
similar degree in all organs (Fig. 5b). Interestingly, pSMAD1 was also
increased in PCKS and PCIS, but not in PCLS. We noticed that in PCIS,
48 h culture induced a much more pronounced change in pSMAD1
protein expression (fold change 92.75 ± 57.72) than in pSMAD2 (fold
change 6.72 ± 1.31). Treatment with 10 μM galunisertib inhibited the
phosphorylation of SMAD2 in all tissue slices, without aﬀecting
pSMAD1.
To explore the activity of non-canonical TGFβ pathways in PCTS,
we measured mRNA expression of Traf6, Map3k7, Mapk1, Rock1 and
Rock2 (Fig. 6). TGFβ promotes K63 polyubiquitination of tumor ne-
crosis factor receptor-associated factor 6 (TRAF6) that activates TGFβ-
associated kinase 1 (TAK1) encoded by Map3k7, which are speciﬁcally
required for activating JNK, p38 and NF-kB [18,39]. In turn, Mapk1
encodes ERK2 – a kinase involved in TGFβ-induced ERK-MAPK sig-
nalling. Rho-associated kinases ROCK1 and ROCK2 are the downstream
targets of the small GTPases RhoA, RhoB, and RhoC. The baseline
mRNA expression of tested markers was signiﬁcantly higher in PCIS
compared to other tissue slices, except for Traf6, of which baseline
expression was similar in all organs. Furthermore, culture-induced
TGFβ activated MAPK, NF-kB and Rho-like GTPases signalling cascades
in PCLS and PCKS, as reﬂected by signiﬁcant increase in gene expres-
sion of all ﬁve markers. The eﬀect in PCIS was the opposite: Mapk1 and
Rock1 were downregulated at 48 h, other transcripts also showed a
decreased expression, although not statistically signiﬁcant. As expected,
galunisertib had no impact on activation of non-canonical pathways.
3.4. Transcription factors in PCTS
Lastly, we attempted to identify which transcription factors (TFs)
are involved in the onset of ﬁbrosis in PCTS. TFs are a large family of
proteins that control the transcription of genes, and are often expressed
in a tissue and stress-speciﬁc manner. We measured mRNA expression
of four TFs, namely Yy1, Nfkb1, Stat3, and Egr1 (Fig. 7). These TFs are
of interest due to their established connection to ECM regulation or
TGFβ signalling. Brieﬂy, Ying Yang 1 (YY1) protein is involved in the
transcription of α1 and α2 collagen type I gene [40,41]. Early growth
Fig. 3. Transcriptional analysis of murine precision-cut tissue slices after 48 h culture or treatment with galunisertib. (a–c) Heatmaps of the results of TaqMan low-
density array (TLDA) analysis illustrating log2 fold changes in the expression of extracellular matrix related genes in PCIS (a), PCLS (b) and PCKS (c) after 48 h culture
or treatment with 10 μM galunisertib. Fold changes displayed in these heatmaps were calculated as relative to the average expression in the corresponding 0 h control
slices. Red and blue indicate relatively high and low expression, respectively (grey color indicates undetermined values). Row min and max expression levels were
determined for each row separately, therefore min and max values are unique for each analyzed gene. Unsupervised clustering analysis is performed by average-
linkage clustering method using Pearson correlation; n= 3. Fold changes and results of the statistical analyses are shown in Supplementary Table S5. (d–e) Number
of genes that were not regulated or statistically signiﬁcantly altered in expression in PCIS, PCLS and PCKS during 48 h culture (d) and due to the treatment with
10 μM galunisertib (e). (f–h) Venn diagrams illustrating the overlapping and unique genes among PCTS that were diﬀerentially regulated during 48 h culture (f), were
aﬀected by 10 μM galunisertib (g) or remained unchanged after the treatment (h).
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response-1 (EGR-1) also mediates TGFβ-induced collagen type I tran-
scription, although in a SMAD-independent manner involving MAPK-
ERK signalling [42,43]. In turn, TGFβ-mediated activity of NF-kB often
requires cooperation with SMADs as transcriptional coactivators to
regulate the transcription of its target genes [44], whereas activation of
the signal transducer and activator of transcription 3 (STAT3) by TGFβ
requires integrated signals from phosphorylated SMAD3 and non-ca-
nonical kinases such as JAK1 [45].
Culturing for 48 h resulted in marked upregulation of all tested TFs
in PCLS and PCKS. In contrast, PCIS only displayed a culture-induced
upregulation of Egr1, while expression of other TFs remained un-
changed. The 48 h treatment with galunisertib attenuated culture-in-
duced activation of transcription factors Nfkb1, Stat3 and Yy1 in PCLS
and PCKS, but not in PCIS. Gene expression of Egr1 remained un-
changed in tissue slices after 48 h treatment.
4. Discussion
In this article, we investigated the heterogeneity of organ ﬁbrosis.
To this end, we prepared murine precision-cut tissue slices from intes-
tine, liver and kidneys and studied changes in ECM homeostasis, onset
of inﬂammation and ﬁbrosis and activation of TGFβ signalling prior to
culturing, after 48 h of culture or following the treatment with galu-
nisertib, a TGFβRI/ALK5 kinase inhibitor. We provide evidence that,
despite the many common features of ﬁbrotic diseases, each organ re-
sponds diﬀerently to injury and, thus may not have similar suscept-
ibility to antiﬁbrotic therapy.
At baseline, precision-cut tissue slices displayed substantial organ
diﬀerences, as a total of 70% of ECM-related transcripts were found to
be diﬀerentially expressed in mouse intestine, liver and kidney. These
diﬀerences may arise from ﬁbroblast phenotypic heterogeneity [46,47]
or from the fact that cell type composition varies between these organs,
as well as the sources of myoﬁbroblasts [48]. The baseline proﬁle may
impact further responses of the slices during culture.
Slice preparation, which entails cold ischemia and mechanic
trauma, and culturing have a great impact on tissue slices: mouse in-
testinal, liver and kidney slices show extensive changes in ECM reg-
ulation and develop early ﬁbrogenic as well as inﬂammatory responses
after 48 h incubation. Similar culture-induced responses were pre-
viously reported in PCIS [20], PCLS [49] and PCKS [24]. In this study,
we demonstrate that the magnitude of these changes varies by tissue
type: culture-induced eﬀects were most pronounced in PCKS and the
least in PCIS. Matrix remodelling is a critical component of ﬁbrosis [4],
and our results show that all tested organ slices shared culture-induced
changes in the gene expression of collagen type I (α1 and α2) and III,
ﬁbronectin, LOXL2, an enzyme that promotes collagen production [50],
as well as HSP47 and FKBP65 that act as chaperones of type I collagen
[51,52], among others. All tissue slices also showed a dramatic upre-
gulation of Mmp13 and Timp1, further suggesting extensive matrix re-
modelling during culture, as it has been shown that TIMP1 is upregu-
lated during ﬁbrogenesis in mouse models and in humans [53–55] and
increased levels of MMP13 promote ﬁbrosis [56–58]. Exposure of PCTS
to 80% oxygen during culture also leads to an increased production of
reactive oxygen species (ROS). In this case, it is likely that the oxidative
stress also contributes to the onset of spontaneous inﬂammation and
ﬁbrogenesis in PCTS; however, the exact role of ROS and oxidative
stress in the PCTS model requires further investigation.
Despite the shared similarities in ECM regulation, culture-induced
changes in intestinal slices markedly diﬀered from the other tissue
slices. The majority of the studied genes were upregulated in PCLS and
PCKS, whereas nearly half of the transcripts were alternatively regu-
lated in PCIS. For instance, genes encoding collagen type I (α1 and α2),
type III and alpha-SMA were among those with reduced expression in
PCIS during culture. Collagen is secreted as a soluble procollagen mo-
lecule with an NH2- (N) and a COOH (C)-terminal propeptide, and the
removal of these propeptides is essential for the formation of insoluble
collagen ﬁbers [59]. Bone morphogenic protein (BMP) 1 enzymatically
cleaves the C-terminal propeptide [60], while two enhancer proteins –
procollagen C-endopeptidase enhancer (PCOLCE) 1 and 2 – increase
catalytic activity of BMP-1 for ﬁbrillar procollagens in vitro [61,62].
BMP-1 expression increases in response to ﬁbrotic deposition of col-
lagen [63]; however our study showed that intestinal expression of
Bmp1 remained unchanged during culture. Furthermore, expression of
both Pcolce and Pcolce2 were downregulated in PCIS at 48 h. These
observations contradict the published work that reported on increased
mRNA levels of collagen type I, III and V in ﬁbroblasts isolated from
patients with Crohn's disease [64,65]. Regarding the expression of α-
SMA in PCIS, the discordance between its gene and protein levels at
48 h could be attributed to the diﬀerences in rate of transcriptional and
translational processes and/or the half-lives of transcripts and proteins
[66]. Further elucidation of the mechanisms of collagen type I and α-
SMA transcriptional regulation in PCIS is, therefore, needed.
As a part of our interest in elucidating inter-organ diﬀerences, we
investigated one of the core ﬁbrosis pathways – the TGFβ pathway.
TGFβ pathway was activated during culture in all tissue slices; how-
ever, the involvement of canonical (SMAD-dependent) and non-cano-
nical (SMAD-independent) signalling cascades was diﬀerent across the
organs. In PCLS and PCKS, all tested TGFβ-mediated pathways were
activated during culture, namely TGFβRI/ALK5/SMAD2, MAPK-JNK/
p38/ERK, NF-kB and Rho-like GTPases. In contrast, in PCIS, only the
canonical TGFβ signalling cascade was actively involved in the onset of
ﬁbrosis. Furthermore, among all tissue slices, PCIS displayed a stronger
culture-induced activation of TGFβRI/ALK1/SMAD1 than of ALK5/
SMAD2. There is an increasing number of studies reporting that the
TGFβRI/ALK1/SMAD1 pathway is involved in organ ﬁbrosis [38].
TGFβ signalling via ALK1 receptor and SMAD1, SMAD5 and SMAD8
promotes endothelial proliferation and migration and acts as an an-
tagonistic mediator of ALK5/SMAD2/3-induced ECM protein expres-
sion [67,68]. It has been reported that ALK1 inhibits, while ALK5 po-
tentiates, TGFβ-induced SMAD2-dependent transcriptional activity and
the expression of ECM components in human chondrocytes and en-
dothelial cells [69,70]. Therefore, it might be possible that high activity
of TGFβRI/ALK1/SMAD1 signalling in PCIS plays a role in the observed
downregulation of ECM- and ﬁbrosis-related genes in PCIS during cul-
ture.
The treatment with galunisertib selectively blocked SMAD2 phos-
phorylation in all tissue slices, regardless of the organ of origin, without
aﬀecting pSMAD1 or non-canonical TGFβ signalling cascades.
However, galunisertib only reduced the expression of the TGFβ
pathway markers (Tgfb1, Tgfbr1 and Serpine1) in PCKS, but not in PCLS
or PCIS. Recently, Luangmonkong et al. reported that 10 μM galuni-
sertib blocked SMAD2 phosphorylation in rat and human PCLS, but
aﬀected Tgfb1 expression only in human liver slices [22]. Of note, this
study also investigated the eﬀects of TGFβ1 on rat and human PCLS
Fig. 4. Baseline expression, culture-induced eﬀects and impact of TGFβRI/ALK5 inhibitor on markers of ﬁbrogenesis in murine precision-cut tissue slices. (a)
Expression of Col1a1, Acta2, Serpinh1 and Fn1mRNA levels were measured by RT-qPCR in PCIS, PCLS and PCKS at 0 h (baseline), after 48 h culture or treatment with
10 μM galunisertib. Results are shown as 2−ΔCt values normalized to Gapdh. Data are presented as mean ± SEM, n= 3. (*) denotes statistical diﬀerences in baseline
levels or diﬀerences between 0 h and 48 h slices of the same organ, while (#) denotes statistical diﬀerences between slices from diﬀerent organs at 48 h; p < 0.05. (b)
Protein expression levels of α-SMA and HSP47 were examined in by Western blot. Representative gel electrophoresis bands are shown along with the quantiﬁcation
results of densitometry. Protein expression was normalized for total protein load and expressed as relative value to the control group. Data are presented as
mean ± SEM, n=4–5, *p < 0.05.
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during culture and in presence of galunisertib. Studies on hepatocel-
lular carcinoma also found a signiﬁcant reduction of Tgfb1 and Tgfbr1
mRNA levels by galunisertib in vivo in mice and ex vivo in human tumor
tissue [71,72]. These ﬁndings suggest that along with organ-diﬀer-
ences, the eﬀect of galunisertib varies between species and is possibly
more pronounced in tissues with an established pathological state.
Following the observation that galunisertib downregulated Tgfb1,
Tgfbr1 and Serpine1 only in kidney slices, our results demonstrate that
galunisertib mitigated culture-induced changes in ECM homeostasis
and early ﬁbrogenesis most eﬀectively in PCKS, showed moderate ac-
tivity in PCLS and had only limited eﬀect in PCIS. Most of the tested

















































































































































































































































































































































































































































































































































































































































































































































Fig. 5. Baseline expression, culture-induced eﬀects and impact of TGFβRI/ALK5 inhibitor on TGFβ signalling in murine precision-cut tissue slices. (a) Expression of
Tgfb1, Tgfbr1 and Serpine1mRNA levels were measured by RT-qPCR in PCIS, PCLS and PCKS at 0 h (baseline), after 48 h culture or treatment with 10 μM galunisertib.
Results are shown as 2−ΔCt values normalized to Gapdh. Data are presented as mean ± SEM, n=3. (*) denotes statistical diﬀerences in baseline levels or diﬀerences
between 0 h and 48 h slices of the same organ, while (#) denotes statistical diﬀerences between slices from diﬀerent organs at 48 h; p < 0.05. (b) Protein expression
levels of pSMAD2 and pSMAD1 were examined in by Western blot. Representative gel electrophoresis bands are shown along with the quantiﬁcation results of
densitometry. Protein expression was normalized for total protein load and expressed as relative value to the control group. Data are presented as mean ± SEM,
n= 4–5, *p < 0.05.
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SMAD2 dependent manner in kidney, but not in intestine, emphasizing
that ECM homeostasis and early ﬁbrogenesis are regulated diﬀerently
in these organs. Notably, ex vivo activity of galunisertib in PCLS
(healthy and ﬁbrotic) falls in line with recent in vivo studies that
showed antiﬁbrotic potency of galunisertib in liver ﬁbrosis, which was
mainly associated with ECM remodelling [73,74]. We speculate that
similarly, antiﬁbrotic eﬀects of galunisertib in PCKS might translate
into mitigation of renal ﬁbrosis in vivo.
Interestingly, while galunisertib inhibited mRNA expression of col-
lagen type I (α1) and III in all tissue slices, the treatment had no impact
on collagen type IV as well as on Leprel1 gene, encoding P3H enzyme
responsible for modifying type IV collagens [75]. Diﬀerent types of
collagen vary in their structure, assembly and function. Types I and III
collagens belong to the family of ﬁbril-forming collagens that are lar-
gely present in ECM, whereas type IV collagen is the main structural



















































































































































































































































































































































































































































































































































Fig. 6. Baseline expression, culture-induced eﬀects and impact of TGFβRI/ALK5 inhibitor on non-canonical TGFβ signalling in murine precision-cut tissue slices.
Expression of Traf6, Map3k7, Mapk1, Rock1 and Rock2 mRNA levels were measured by RT-qPCR in PCIS, PCLS and PCKS at 0 h (baseline), after 48 h culture or
treatment with 10 μM galunisertib. Results are shown as 2−ΔCt values normalized to Gapdh. Data are presented as mean ± SEM, n= 3. (*) denotes statistical
diﬀerences in baseline levels or diﬀerences between 0 h and 48 h slices of the same organ, while (#) denotes statistical diﬀerences between slices from diﬀerent organs
at 48 h; p < 0.05.
E. Bigaeva, et al. BBA - Molecular Basis of Disease 1866 (2020) 165582
11
collagen types also diﬀers in tissue slices, as expression of Col4a1 seems
to be TGFβ-independent, in contrast to Col1a1 and Col3a1.
In addition, we investigated the expression of several transcriptional
factors (TFs) in PCTS during culture and after galunisertib treatment.
Guo et al. demonstrated that TGFβ induced the expression of YY1 in
lung ﬁbroblasts, which in turn can directly regulate αSMA and collagen
expression [77]. We did not observe an increase in Yy1 expression in
PCIS during culture; this could explain the absence of induction of the
expression of Col1a1 and Acta2 during culture. In general, TFs that
operate in a SMAD-dependent manner (Yy1, Stat3, Nfkb1) were aﬀected
by galunisertib treatment in both PCLS and PCKS, while those that are
SMAD-independent (Egr1) were not.
5. Conclusion
Taken together, our study details the organ-speciﬁc features of ﬁ-
brosis in murine intestine, liver and kidney slices. PCTS, as an ex vivo
ﬁbrosis model, reﬂects the diversity of the responses that are speciﬁc to
the organ and species. Furthermore, our results revealed that treatment
with TGFβRI/ALK5 kinase inhibitor elicits varying eﬀects in PCTS,
conﬁrming that organs do not display similar susceptibility to anti-
ﬁbrotic therapy, even though it targets a core ﬁbrosis pathway. The
following limitations of the PCTS model have to be considered: (1)
relatively short culture period might not fully demonstrate changes on a
translational level; (2) inﬂuence of the immune system cannot be di-
rectly assessed and (3) complexity of a multi-organ system cannot be
replicated. Our ﬁndings provide the foundation for future investigations
of the unique organ features within the common pathology – ﬁbrosis. A
better understanding of the processes and mechanisms that contribute
to organ ﬁbrosis may stimulate a hybrid approach for the drug devel-
opment – targeting core ﬁbrosis-regulating factors in an organ-speciﬁc
manner. Therefore, new in-depth studies of precision-cut tissue slices of
mouse and human origin using advanced genomic and proteomic
technologies, among others, are needed.
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Fig. 7. Regulation of selected transcription factors in murine precision-cut tissue slices. Expression of Nfkb1, Stat3, Yy1 and Egr1 mRNA levels were measured by RT-
qPCR in PCIS, PCLS and PCKS at 0 h (baseline), after 48 h culture or treatment with 10 μM galunisertib. Results are shown as 2−ΔCt values normalized to Gapdh. Data
are presented as mean ± SEM, n= 3. (*) denotes statistical diﬀerences in baseline levels or diﬀerences between 0 h and 48 h slices of the same organ, while (#)
denotes statistical diﬀerences between slices from diﬀerent organs at 48 h; p < 0.05.
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